A drug that originally cost $8,700 a year now costs $62,400 a year.
News
The approval comes after Teva Pharmaceuticals filed eight citizen petitions and fought several court battles to protect Copaxone.
The trial will evaluate the use of memory and external aids, like cell phones, for memory recall in multiple sclerosis.
Participants in MS trials want full disclosure from physicians about financial relationships with the industry.
Two studies, one from the U.S. and one from Sweden, had consistent results.
Researchers have yet to conclude whether the levels are caused by MS or are a result of the disease.
Teva is in the process of converting patients to a new, patent-protected version of Copaxone.
In western countries, the rate of H. pylori infections have dropped as MS has become more prevalent.
The findings further support the safety of the vaccine.
Researchers saw sustained remission, neurologic improvement over three years.
NEDA can be used to evaluate the effectiveness of new MS drugs.
Seasonal relapse in multiple sclerosis occurs in both hemispheres but varies by latitude.
There is currently no approved treatments for RMS that have been shown to change the course of the disease.
PML infections have been reported in other drugs used to treat multiple sclerosis.
Targeted exercise therapies can improve postural control in MS patients with balance and mobility problems.
